R
Runlin Gao
Researcher at Peking Union Medical College
Publications - 545
Citations - 10474
Runlin Gao is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: Percutaneous coronary intervention & Myocardial infarction. The author has an hindex of 42, co-authored 487 publications receiving 7504 citations. Previous affiliations of Runlin Gao include Peking University & Cardiovascular Institute of the South.
Papers
More filters
Journal ArticleDOI
Status of Hypertension in China: Results From the China Hypertension Survey, 2012-2015.
Zengwu Wang,Zuo Chen,Linfeng Zhang,Xin Wang,Guang Hao,Zugui Zhang,Lan Shao,Ye Tian,Ying Dong,Congyi Zheng,Jiali Wang,Manlu Zhu,William S. Weintraub,Runlin Gao +13 more
TL;DR: In China, there is a high prevalence of hypertension (HTN) and pre-HTN, and awareness, treatment, and control of HTN were low, and management of medical therapy for HTN needs to improve.
Journal ArticleDOI
Prevalence, awareness, treatment, and control of hypertension in China data from the China National Nutrition and Health Survey 2002
Yangfeng Wu,Rachel R. Huxley,Liming Li,Vibeke Anna,Gaoqiang Xie,Chong-hua Yao,Mark Woodward,Mark Woodward,Xian Li,John Chalmers,Runlin Gao,Lingzhi Kong,Xiaoguang Yang +12 more
TL;DR: One in 6 Chinese adults is hypertensive, but only one quarter are aware of their condition, and despite increased rates of blood pressure–lowering treatment, few have their hypertension effectively controlled.
Journal ArticleDOI
Quality of primary health care in China: challenges and recommendations.
Xi Li,Harlan M. Krumholz,Winnie Yip,Kar Keung Cheng,Kar Keung Cheng,Jan De Maeseneer,Qingyue Meng,Elias Mossialos,Chuang Li,Jiapeng Lu,Meng Su,Qiuli Zhang,Qiuli Zhang,Dong Xu,Liming Li,Sharon-Lise T. Normand,Sharon-Lise T. Normand,Richard Peto,Jing Li,Zengwu Wang,Hongbing Yan,Runlin Gao,Somsak Chunharas,Xin Gao,Raniero Guerra,Huijie Ji,Yang Ke,Zhigang Pan,Xianping Wu,Shuiyuan Xiao,Xinying Xie,Yujuan Zhang,Jun Zhu,Shanzhu Zhu,Shengshou Hu +34 more
TL;DR: China has substantially increased financial investment and introduced favourable policies for strengthening its primary health care system with core responsibilities in preventing and managing chronic diseases such as hypertension and emerging infectious disease 2019 (COVID-19).
Journal ArticleDOI
A Phase II, Randomized, Double-Blind, Multicenter, Based on Standard Therapy, Placebo-Controlled Study of the Efficacy and Safety of Recombinant Human Neuregulin-1 in Patients With Chronic Heart Failure
Runlin Gao,Jian Zhang,Liuquan Cheng,Xuesi Wu,Wei Dong,Xinchun Yang,Tianchang Li,Xifu Liu,Yabei Xu,Xinyan Li,Mingdong Zhou +10 more
TL;DR: In this article, the safety and efficacy of recombinant human neuregulin-1 (rhNRG-1) in chronic heart failure (CHF) patients were evaluated. But, the authors did not evaluate the effect of rhNRG on the LVEF.
Journal ArticleDOI
China cardiovascular diseases report 2018: an updated summary
Li-Yuan Ma,Wei-wei Chen,Runlin Gao,Lisheng Liu,Manlu Zhu,Yong-Jun Wang,Zhao-Su Wu,Hui-Jun Li,Dong-Feng Gu,Yuejin Yang,Zhe Zheng,Sheng-shou Hu +11 more
TL;DR: An updated summary of the Report on Cardiovascular Diseases in China 2018 is presented that includes trends in CVD, the morbidity and mortality of CVD," risk factor assessment, health resources for CVD", and a profile of medical expenditure.